//
Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Dr. Patti Gravitt

Ph.D., M.S.
Titles

Associate Professor
Epidemiology

Joint Departmental Affiliations
Molecular Microbiology and Immunology

Research Summary

Dr. Gravitt's research interests are primarily focused on the molecular epidemiology and detection/screening for human papillomaviruses (HPV) and cervical cancer. She has developed and validated gold standard PCR-based methods for the detection and quantitation of human papillomaviruses.

Dr. Gravitt is currently involved in several projects in the US and abroad:

1) The Community Access to Cervical Health (CATCH) Study is an evaluation of sustainable cervical cancer screening methods in peri-urban India, in collaboration with Dr. Keerti V. Shah, SHARE India/Mediciti Institute of Medical Sciences and the Center for DNA Fingerprinting and Diagnostics.

2) The HPV in Perimenopause (HIP) Study is being conducted in collaboration with Drs. Anne Burke and Raphael Viscidi at Johns Hopkins Hospital-affiliated clinics in the Baltimore Metropolitan area. The HIP study aims to describe the natural history of genital HPV infection through the menopausal transition.

3) The HPV and hormonal contraceptives study is being conducted in collaboration with Dr. David Celentano (JHSPH). This study of women 18-35 years in Thailand aims to evaluate the effect of combined oral contraceptive and injectable progesterone use on the early natural history of HPV infections.

4) The HPV-aHIV study is being conducted in collaboration with Drs. David Celentano (JHSPH) and Charlie Morrison (FHI). This study aims to evaluate the effect of acute HIV infection on the detectability of cervical HPV.

5) In collaboration with Drs. Ron Gray and Maria Wawer (JHSPH), Dr. Gravitt’s laboratory is investigating the effect of adult male circumcision on HPV prevalence in men participating in a randomized controlled trial in Rakai, Uganda.

Dr. Gravitt also has active collaborations with the basic sciences, including a study of the role of nitric oxide on HPV-associated carcinogenesis with Dr. Michelle Ozbun (UNM) and a study of the immunologic effects of female sex steroid combinations on immune response to HPV VLP in collaboration with Dr. Sabra Klein (JHSPH). Dr. Gravitt’s laboratory works closely with intramural investigators at the Division of Cancer Epidemiology and Genetics (Drs. Phil Castle, Sophia Wang, Mark Schiffman, Allan Hildesheim, Jill Koshiol, Sandy Dawson, and Phil Taylor), evaluating HPV type and viral load from large cervical cancer screening studies (e.g., Mississippi Delta Project, ALTS, Costa Rica Vaccine Trial) and case-control studies of cervical neoplasia (SUCCEED) and esophageal cancer.
 

Journal Citations

Bhatla, N.; Dar, L.; Rajkumar Patro, A.; Kumar, P.; Pati, S.K.; Kriplani, A.; Gulati, A.; Broor, S.; Iyer, V.K.; Mathur, S.; Shah, K.V.; Gravitt, P.E. Human papillomavirus-type distribution in women with and without cervical neoplasia in north India. Int J Gynecol Pathol. 2008 Jul;27(3):426-430.

Hoory, T.; Monie, A.; Gravitt, P.; Wu, T.C. Molecular epidemiology of human papillomavirus. J Formos Med Assoc. 2008 Mar;107(3):198-217.

Roden, R.B.; Gravitt, P.; Wu, T.C. Towards global prevention of human papillomavirus-induced cancer. Eur J Immunol. 2008 Feb;38(2):323-326.

Safaeian, M.; Kiddugavu, M.; Gravitt, P.E.; Gange, S.J.; Ssekasanvu, J.; Murokora, D.; Sklar, M.; Serwadda, D.; Wawer, M.J.; Shah, K.V.; Gray, R. Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1300-1307.

Safaeian, M.; Kiddugavu, M.; Gravitt, P.E.; Gange, S.J.; Ssekasanvu, J.; Murokora, D.; Sklar, M.; Serwadda, D.; Wawer, M.J.; Shah, K.V.; Gray, R. Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. Sexually transmitted infections. 2008 Aug;84(4):306-311.

Adelstein, D.J.; Ridge, J.A.; Gillison, M.L.; Chaturvedi, A.K.; D'Souza, G.; Gravitt, P.E.; Westra, W.; Psyrri, A.; Kast, W.M.; Koutsky, L.A.; Giuliano, A.; Krosnick, S.; Trotti, A.; Schuller, D.E.; Forastiere, A.; Ullmann, C.D. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009 Nov;31(11):1393-1422.

Althoff, K.N.; Paul, P.; Burke, A.E.; Viscidi, R.; Sangaramoorthy, M.; Gravitt, P.E. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health (Larchmt). 2009 Sep;18(9):1341-1346.

Andersson, S.; Sowjanya, P.; Wa
ngsa, D.; Hjerpe, A.; Johansson, B.; Auer, G.; Gravitt, P.E.; Larsson, C.; Wallin, K.L.; Ried, T.; Heselmeyer-Haddad, K. Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal pap smears. Am J Pathol. 2009 Nov;175(5):1831-1847.

Bhatla, N.; Dar, L.; Patro, A.R.; Kumar, P.; Kriplani, A.; Gulati, A.; Iyer, V.K.; Mathur, S.R.; Sreenivas, V.; Shah, K.V.; Gravitt, P.E. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol. 2009 Dec;33(6):446-450.

Gnanamony, M.; Peedicayil, A.;
Subhashini, J.; Ram, T.S.; Christopher, S.; Gravitt, P.; Abraham, P. Human papillomavirus types 16 and 18 mRNA levels and not DNA levels may be associated with advancing stages of cervical cancer. Int J Gynecol Cancer. 2009 Nov;19(8):1415-1420.

Lin, Z.; Yemelyanova, A.V.; Gambhira, R.; Jagu, S.; Meyers, C.; Kirnbauer, R.; Ronnett, B.M.; Gravitt, P.E.; Roden, R.B. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol. 2009 Jan;174(1):136-143.

Marks, M.; Gupta, S.B.; Liaw, K.L.; Kim, E.; Tadesse, A.; Coutlee, F.; Sriplienchan, S.; Celentano, D.D.; Gravitt, P.E. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time PCR. J Virol Methods. 2009 Mar;156(1-2):152-156.

Phelan, D.F.; Gange, S.J.; Ahdieh-Grant, L.; Mehta, S.H.; Kirk, G.D.; Shah, K.; Gravitt, P. Determinants of Newly Detected Human Papillomavirus Infection in HIV-Infected and HIV-Uninfected Injection Drug Using Women. Sexually transmitted diseases. 2009 Feb 9.

Sowjanya, A.P.; Paul, P.; Vedantham, H.; Ramakrishna, G.; Vidyadhari, D.; Vijayaraghavan, K.; Laksmi, S.; Sudula, M.; Ronnett, B.M.; Das, M.; Shah, K.V.; Gravitt, P.E.; Community Access to Cervical Health Study, G. Suitability of self-collected vaginal samples for cervical cancer screening in periurban villages in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1373-1378.

Taube, J.M.; Kamira, B.; Motevalli, M.; Nakabiito, C.; Lukande, R.; Kelly, D.P.; Erozan, Y.S.; Gravitt, P.E.; Buresh, M.E.; Mmiro, F.; Bagenda, D.; Guay, L.A.; Jackson, J.B. Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation. Diagnostic cytopathology. 2009 Nov 24.

Tobian, A.A.; Serwadda, D.; Quinn, T.C.; Kigozi, G.; Gravitt, P.E.; Laeyendecker, O.; Charvat, B.; Ssempijja, V.; Riedesel, M.; Oliver, A.E.; Nowak, R.G.; Moulton, L.H.; Chen, M.Z.; Reynolds, S.J.; Wawer, M.J.; Gray, R.H. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009 Mar 26;360(13):1298-1309.

Trimble, C.L.; Peng, S.; Kos, F.; Gravitt, P.; Viscidi, R.; Sugar, E.; Pardoll, D.; Wu, T.C. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009 Jan 1;15(1):361-367.

Wei, L.; Gravitt, P.E.; Song, H.; Maldonado, A.M.; Ozbun, M.A. Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res. 2009 Jun 1;69(11):4878-4884.

Wentzensen, N.; Gravitt, P.E.; Solomon, D.; Wheeler, C.M.; Castle, P.E. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1341-1349.

Yemelyanova, A.; Vang, R.; Seidman, J.D.; Gravitt, P.E.; Ronnett, B.M. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol. 2009 Jun;33(6):914-924.

Yu, K.J.; Hsu, W.L.; Chiang, C.J.; Cheng, Y.J.; Pfeiffer, R.M.; Diehl, S.R.; Goldstein, A.M.; Gravitt, P.E.; Chen, C.J.; Hildesheim, A. Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. Int J Cancer. 2009 Apr 1;124(7):1622-1625.

Castle, P.E.; Schiffman, M.; Wheeler, C.M.; Wentzensen, N.; Gravitt, P.E. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol. 2010 Jan 15;171(2):155-163.

Castle, P.E.; Schiffman, M.; Wheeler, C.M.; Wentzensen, N.; Gravitt, P.E. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1675-1681.

Gravitt, P.E.; Kirk, G.D. Progress and pitfalls in defining the influence of highly active antiretroviral therapy on human papillomavirus-associated cervical disease. J Infect Dis. 2010 Mar;201(5):650-652.

Gravitt, P.E.; Paul, P.; Katki, H.A.; Vendantham, H.; Ramakrishna, G.; Sudula, M.; Kalpana, B.; Ronnett, B.M.; Vijayaraghavan, K.; Shah, K.V. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One. 2010;5(10):e13711.

Gray, R.H.; Serwadda, D.; Kong, X.; Makumbi, F.; Kigozi, G.; Gravitt, P.E.; Watya, S.; Nalugoda, F.; Ssempijja, V.; Tobian, A.A.; Kiwanuka, N.; Moulton, L.H.; Sewankambo, N.K.; Reynolds, S.J.; Quinn, T.C.; Iga, B.; Laeyendecker, O.; Oliver, A.E.; Wawer, M.J. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis. 2010 May 15;201(10):1455-1462.

Koshiol, J.; Wei, W.Q.; Kreimer, A.R.; Chen, W.; Gravitt, P.; Ren, J.S.; Abnet, C.C.; Wang, J.B.; Kamangar, F.; Lin, D.M.; von Knebel-Doeberitz, M.; Zhang, Y.; Viscidi, R.; Wang, G.Q.; Gillison, M.L.; Roth, M.J.; Dong, Z.W.; Kim, E.; Taylor, P.R.; Qiao, Y.L.; Dawsey, S.M. No role for human papillomavirus in esophageal squamous cell carcinoma in China. Int J Cancer. 2010 Jul 1;127(1):93-100.

Marks, M.A.; Gravitt, P.E.; Burk, R.D.; Studentsov, Y.; Farzadegan, H.; Klein, S.L. Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol. 2010 Apr;17(4):609-617.

Piyathilake, C.J.; Badiga, S.; Paul, P.; Vijayaraghavan, K.; Vedantham, H.; Sudula, M.; Sowjanya, P.; Ramakrishna, G.; Shah, K.V.; Partridge, E.E.; Gravitt, P.E. Indian women with higher serum concentrations of folate and vitamin B12 are significantly less likely to be infected with carcinogenic or high-risk (HR) types of human papillomaviruses (HPVs). Int J Womens Health. 2010;2:7-12.

Schweizer, J.; Lu, P.S.; Mahoney, C.W.; Berard-Bergery, M.; Ho, M.; Ramasamy, V.; Silver, J.E.; Bisht, A.; Labiad, Y.; Peck, R.B.; Lim, J.; Jeronimo, J.; Howard, R.; Gravitt, P.E.; Castle, P.E. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol. 2010 Dec;48(12):4646-4648.

Vedantham, H.; Silver, M.I.; Kalpana, B.; Rekha, C.; Karuna, B.P.; Vidyadhari, K.; Mrudula, S.; Ronnett, B.M.; Vijayaraghavan, K.; Ramakrishna, G.; Sowjanya, P.; Laxmi, S.; Shah, K.V.; Gravitt, P.E. Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1373-1380.

Wentzensen, N.; Wilson, L.E.; Wheeler, C.M.; Carreon, J.D.; Gravitt, P.E.; Schiffman, M.; Castle, P.E. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. Cancer Res. 2010 Nov 1;70(21):8578-8586.

Bhatla, N., Dar, L., Rajkumar Patro, A., Kumar, P., Pati, S.K., Kriplani, A., Gulati, A., Broor, S., Iyer, V.K., Mathur, S., Shah, K.V., and Gravitt, P.E. (2008). Human papillomavirus-type distribution in women with and without cervical neoplasia in north India. Int J Gynecol Pathol 27, 426-430.

D'Souza, G., Sugar, E., Ruby, W., Gravitt, P. & Gillison, M. (2005). Analysis of the effect of DNA purification on detection of human papillomavirus in oral rinse samples by PCR. J Clin Microbiol 43, 5526-35.

Eberhart, C. G., Chaudhry, A., Daniel, R. W., Khaki, L., Shah, K. V. & Gravitt, P. E. (2005). Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer 5, 19.

Hoory, T., Monie, A., Gravitt, P., and Wu, T.C. (2008). Molecular epidemiology of human papillomavirus. J Formos Med Assoc 107, 198-217.

Safaeian, M., Kiddugavu, M., Gravitt, P.E., Gange, S.J., Ssekasanvu, J., Murokora, D., Sklar, M., Serwadda, D., Wawer, M.J., Shah, K.V., and Gray, R. (2008). Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev 17, 1300-1307.

Safaeian, M., Kiddugavu, M., Gravitt, P.E., Gange, S.J., Ssekasanvu, J., Murokora, D., Sklar, M., Serwadda, D., Wawer, M.J., Shah, K.V., and Gray, R. (2008). Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. Sex Transm Infect 84, 306-311.

Trimble, C. L., Piantadosi, S., Gravitt, P., Ronnett, B., Pizer, E., Elko, A., Wilgus, B., Yutzy, W., Daniel, R., Shah, K., Peng, S., Hung, C., Roden, R., Wu, T. C., Pardoll, D. (2005). Spontaneous regression of high-grade cervical dysplasia: Effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11, 4717-4723.

Trimble, C.L., Peng, S., Kos, F., Gravitt, P., Viscidi, R., Sugar, E., Pardoll, D., and Wu, T.C. (2009). A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15, 361-367.

1: Phelan DF, Gange SJ, Ahdieh-Grant L, Mehta SH, Kirk GD, Shah K, Gravitt P. Determinants of Newly Detected Human Papillomavirus Infection in HIV-Infected and HIV-Uninfected Injection Drug Using Women. Sex Transm Dis. 2009 Jan 23. [Epub ahead of print]

2: Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009 Jan 1;15(1):361-7.

3: Lin Z, Yemelyanova AV, Gambhira R, Jagu S, Meyers C, Kirnbauer R, Ronnett BM, Gravitt PE, Roden RB. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2.

Am J Pathol. 2009 Jan;174(1):136-43. Epub 2008 Dec 18.

4: Yu KJ, Hsu WL, Chiang CJ, Cheng YJ, Pfeiffer RM, Diehl SR, Goldstein AM, Gravitt PE, Chen CJ, Hildesheim A. Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. Int J Cancer. 2009 Apr 1;124(7):1622-5.

5: Marks M, Gupta SB, Liaw KL, Kim E, Tadesse A, Coutlee F, Sriplienchan S, Celentano DD, Gravitt PE. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array((c)) using HPV52-specific TaqMan((c)) E6/E7 quantitative real-time PCR. J Virol Methods. 2008 Dec 5. [Epub ahead of print]

6: Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene BM. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine. 2008 Aug 19;26 Suppl 12:M43-52. Review.

7: Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine. 2008 Aug 19;26 Suppl 10:K42-52. Review.

8: Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008 Dec;32(12):1835-53.

9: Castle PE, Porras C, Quint WG, Rodriguez AC, Schiffman M, Gravitt PE, González P, Katki HA, Silva S, Freer E, Van Doorn LJ, Jiménez S, Herrero R, Hildesheim A; CVT Group. Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol. 2008 Oct;46(10):3437-45. Epub 2008 Aug 20.

10: Bhatla N, Dar L, Rajkumar Patro A, Kumar P, Pati SK, Kriplani A, Gulati A, Broor S, Iyer VK, Mathur S, Shah KV, Gravitt PE. Human papillomavirus-type distribution in women with and without cervical

neoplasia in north India. Int J Gynecol Pathol. 2008 Jul;27(3):426-30.

11: Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol. 2008 Aug;46(8):2595-604. Epub 2008 Jun 25.

12: Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R.

Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1300-7.

13: Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1248-54.

14: Hoory T, Monie A, Gravitt P, Wu TC. Molecular epidemiology of human papillomavirus. J Formos Med Assoc. 2008 Mar;107(3):198-217. Review.

15: Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R. Prevalence and risk factors for carcinogenic human papillomavirus infections in

rural Rakai, Uganda. Sex Transm Infect. 2008 Aug;84(4):306-11. Epub 2008 Apr 2.

16: Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol. 2008 Apr;111(4):847-56.

17: Ferreccio C, Corvalán A, Margozzini P, Viviani P, González C, Aguilera X, Gravitt PE. Baseline assessment of prevalence and geographical distribution of HPV types in Chile using self-collected vaginal samples. BMC Public Health. 2008 Feb 28;8:78.

18: Roden RB, Gravitt P, Wu TC. Towards global prevention of human papillomavirus-induced cancer. Eur J Immunol. 2008 Feb;38(2):323-6. Review. No abstract available.

19: Wongworapat K, Keawvichit R, Sirirojn B, Dokuta S, Ruangyuttikarn C, Sriplienchan S, Sontirat A, Kla KT, Gravitt PE, Celentano DD. Detection of human papillomavirus from self-collected vaginal samples of women in Chiang Mai, Thailand. Sex Transm Dis. 2008 Feb;35(2):172-3.

20: Kahn SL, Ronnett BM, Gravitt PE, Gustafson KS. Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests. Cancer. 2008 Feb 25;114(1):57-64.

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer